Adaptive Biotechnologies banks $195M for NGS; Juno bets $13M on Fate's platform;

@FierceBiotech: Ebola outbreak spurs a new antibody screening project at Theraclone. More from FierceBiotechResearch | Follow @FierceBiotech

@JohnCFierce: If Big Pharma takes over Kendall Sq the biotechs are going to have to move somewhere else. What's the new Brooklyn in Boston? | Follow @JohnCFierce

> Juno Therapeutics ($JUNO) has partnered up with Fate Therapeutics ($FATE) in a four-year research collaboration combining the former's T cell technology with the latter's small-molecule R&D platform. Juno will pay its partner $5 million up front and buy $8 million worth of Fate's shares, promising as much as $50 million for each resulting product. Fate's shares jumped almost 40% on the deal. Release

> Gene sequencing upstart Adaptive Biotechnologies raised $195 million in Series F financing, cash that will help support its efforts to decode targets for T cell therapy and expand the use of its platform technology. More

> GlaxoSmithKline ($GSK) has nixed its plans to sell off a stake of its ViiV Healthcare in an IPO, deciding to hold on to its share of a business co-owned with Pfizer ($PFE) and Shionogi. News

Medical Device News

@FierceMedDev: ICYMI yesterday: Abiomed gains on strong Impella revenue, with U.S. sales ramp to come after recent FDA approval. Article | Follow @FierceMedDev

@EmilyWFierce: Mayne Pharma beefs up U.S. sales ops to revive acne-fighter Doryx. FiercePharmaMarketing report | Follow @EmilyWFierce

> Dozens of hospitals to deploy IBM's Watson computer in fight against cancer. Story

> EndoChoice files for up to $115M IPO to back its wider-view Fuse endoscopy system. Article

Pharma News

@FiercePharma: It's all about that data as IBM Watson Health teams up with J&J, Cleveland Clinic and more. Article | Follow @FiercePharma

@EricPFierce: MHRA concerned with lack of testing by Relonchem , which is owned by India's Marksans Pharma. Report | Follow @EricPFierce

@CarlyHFierce: ICYMI: Merck or Merck KGaA? German Merck beefs up branding to (hopefully) end confusion. Article | Follow @CarlyHFierce

> Embattled GSK scraps ViiV spinoff as pharma revenues tumble. Article

> Caforio takes CEO role as BMS faces tough year with promising new drugs. Report

Biotech Research News

> Scientists highlight link between diabetes and Alzheimer's. Item

> Microparticles amp up the effect of breast cancer vaccines. More

> Johns Hopkins team finds a new drug target for diabetes. Story

> UNC researchers hijack natural 'bubbles' to transport Parkinson's med. Article

> Rodent study once again spotlights role of arginase in hypertension. Report

Diagnostics News

> Abbott grabs FDA OK for early pregnancy blood test. Report

> Myriad Genetics stumbles as rivals flood BRCA market. More

> OpGen sees its shares fall 20% in IPO. Story

> Agilent acquires maker of software for diagnostics laboratories. Article

> RainDance Technologies and Pacific Biosciences partner for whole genome assembly. Item

Pharma Marketing News

> GSK's U.S. Advair sales plummet 22% in Q1--and that's without generics. Item

> The Q1 drug launch scorecard, starring Sanofi, Lilly, Pfizer, Gilead, Merck and more. Report

> Merck or Merck KGaA? German Merck beefs up branding to (hopefully) end confusion. More

> Mayne Pharma bolsters U.S. sales ops to revive acne-fighter Doryx. Article

> It's all about that data as IBM Watson Health teams up with J&J, Cleveland Clinic and more. Story

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.